The present invention addresses the problem of providing: a culture medium that is for adherent culturing of pluripotent stem cells exhibiting high growth ability and that does not contain serum or albumin; and a highly versatile method for adherent culturing of pluripotent stem cells using the culture medium. According to the present invention, by adding, to a culture medium, a hydrophilic polymer that is conventionally known to inhibit adhesion of cells to the surface of a cell culture base material, so that the adhesion of pluripotent stem cell to the surface of the cell culture base material is enhanced, high growth ability is imparted in adherent culturing of pluripotent stem cells without adding serum or albumin thereto. In addition, by adding an antioxidant substance along with such a polymer to a culture medium, very high growth ability is imparted in adherent culturing of pluripotent stem cells.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Natural Treg (nTreg) can potentially suppress cell immune response. Consequently, these CD4+ CD25+ CD127low Foxp3+ T cells are used in adoptive therapy against autoimmune and GVH disease. One difficulty is the varying functional properties depending on the microenvironment that may cause the loss of their suppressive activity and promote TH17- induced inflammatory effects. By ex vivo transdetermination of CD31 TH0 cells, the inventors established and expanded a Foxp3 regulatory T cell population (CD31d-Treg cells) functionally committed to exert a permanent Ag-specific regulatory activity whichever the microenvironmental conditions are. By contrast to nTreg cells, CD31d-Treg cells do not express the IL1 Receptor whose activation is required for IL-17 production. Accordingly, the present invention relates to a population of CD31d-Treg cells functionally committed to exert a regulatory activity and their use for Treg-based adoptive therapy.

Disclosed is a small molecule compound composition that efficiently induces the differentiation of human pluripotent stem cells into myocardial cells. In particular, provided in the present invention is a small molecule compound composition. The small molecule compound composition comprises the following components: (i) an mTOR signaling pathway inhibitor; (ii) a Wnt pathway promoter; and (iii) optionally, a pharmaceutically acceptable carrier. The small molecule compound composition in the present invention can efficiently induce the differentiation of human pluripotent stem cells into myocardial cells. The preliminarily screened cardiomyocyte differentiation rate reaches up to 86%, and the optimized cardiomyocyte differentiation rate reaches up to 98.3%.

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.